Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization

Emmanuelle Godefroy, Yunfeng Liu, Patricia Shi, W. Beau Mitchell, Devin Cohen, Stella T. Chou, Deepa G. Manwani, Karina Yazdanbakhsh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Transfusions are the main treatment for patients with sickle cell disease. However, alloimmunization remains a major life-threatening complication for these patients, but the mechanism underlying pathogenesis of alloimmunization is not known. Given the chronic hemolytic state characteristic of sickle cell disease, resulting in release of free heme and activation of inflammatory cascades, we tested the hypothesis that anti-inflammatory response to heme is compromised in alloimmunized sickle patients, increasing their risk of alloimmunization. Heme-exposed monocyte-derived dendritic cells from both non-alloimmunized sickle patients and healthy donors inhibited priming of proinflammatory CD4+ type 1 T cells, and exhibited significantly reduced levels of the maturation marker CD83. In contrast, in alloimmunized patients, heme did not reverse priming of pro-inflammatory CD4+ cells by monocyte-derived dendritic cells or their maturation. Furthermore, heme dampened NF-kB activation in non-alloimmunized, but not in alloimmunized monocyte-derived dendritic cells. Heme-mediated CD83 inhibition depended on Toll-like receptor 4 but not heme oxygenase 1. These data suggest that extracellular heme limits CD83 expression on dendritic cells in non-alloimmunized sickle patients through a Toll-like receptor 4-mediated pathway, involving NF-kB, resulting in dampening of pro-inflammatory responses, but that in alloimmunized patients this pathway is defective. This opens up the possibility of developing new therapeutic strategies to prevent sickle cell alloimmunization.

Original languageEnglish (US)
Pages (from-to)1028-1038
Number of pages11
JournalHaematologica
Volume101
Issue number9
DOIs
StatePublished - 2016

Fingerprint

Heme
Dendritic Cells
Monocytes
Toll-Like Receptor 4
NF-kappa B
Sickle Cell Anemia
Heme Oxygenase-1
Anti-Inflammatory Agents
Tissue Donors
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Godefroy, E., Liu, Y., Shi, P., Beau Mitchell, W., Cohen, D., Chou, S. T., ... Yazdanbakhsh, K. (2016). Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. Haematologica, 101(9), 1028-1038. https://doi.org/10.3324/haematol.2016.147181

Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. / Godefroy, Emmanuelle; Liu, Yunfeng; Shi, Patricia; Beau Mitchell, W.; Cohen, Devin; Chou, Stella T.; Manwani, Deepa G.; Yazdanbakhsh, Karina.

In: Haematologica, Vol. 101, No. 9, 2016, p. 1028-1038.

Research output: Contribution to journalArticle

Godefroy, E, Liu, Y, Shi, P, Beau Mitchell, W, Cohen, D, Chou, ST, Manwani, DG & Yazdanbakhsh, K 2016, 'Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization', Haematologica, vol. 101, no. 9, pp. 1028-1038. https://doi.org/10.3324/haematol.2016.147181
Godefroy, Emmanuelle ; Liu, Yunfeng ; Shi, Patricia ; Beau Mitchell, W. ; Cohen, Devin ; Chou, Stella T. ; Manwani, Deepa G. ; Yazdanbakhsh, Karina. / Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. In: Haematologica. 2016 ; Vol. 101, No. 9. pp. 1028-1038.
@article{e38a05a0fde844be8cbd84a1a30e5e97,
title = "Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization",
abstract = "Transfusions are the main treatment for patients with sickle cell disease. However, alloimmunization remains a major life-threatening complication for these patients, but the mechanism underlying pathogenesis of alloimmunization is not known. Given the chronic hemolytic state characteristic of sickle cell disease, resulting in release of free heme and activation of inflammatory cascades, we tested the hypothesis that anti-inflammatory response to heme is compromised in alloimmunized sickle patients, increasing their risk of alloimmunization. Heme-exposed monocyte-derived dendritic cells from both non-alloimmunized sickle patients and healthy donors inhibited priming of proinflammatory CD4+ type 1 T cells, and exhibited significantly reduced levels of the maturation marker CD83. In contrast, in alloimmunized patients, heme did not reverse priming of pro-inflammatory CD4+ cells by monocyte-derived dendritic cells or their maturation. Furthermore, heme dampened NF-kB activation in non-alloimmunized, but not in alloimmunized monocyte-derived dendritic cells. Heme-mediated CD83 inhibition depended on Toll-like receptor 4 but not heme oxygenase 1. These data suggest that extracellular heme limits CD83 expression on dendritic cells in non-alloimmunized sickle patients through a Toll-like receptor 4-mediated pathway, involving NF-kB, resulting in dampening of pro-inflammatory responses, but that in alloimmunized patients this pathway is defective. This opens up the possibility of developing new therapeutic strategies to prevent sickle cell alloimmunization.",
author = "Emmanuelle Godefroy and Yunfeng Liu and Patricia Shi and {Beau Mitchell}, W. and Devin Cohen and Chou, {Stella T.} and Manwani, {Deepa G.} and Karina Yazdanbakhsh",
year = "2016",
doi = "10.3324/haematol.2016.147181",
language = "English (US)",
volume = "101",
pages = "1028--1038",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "9",

}

TY - JOUR

T1 - Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization

AU - Godefroy, Emmanuelle

AU - Liu, Yunfeng

AU - Shi, Patricia

AU - Beau Mitchell, W.

AU - Cohen, Devin

AU - Chou, Stella T.

AU - Manwani, Deepa G.

AU - Yazdanbakhsh, Karina

PY - 2016

Y1 - 2016

N2 - Transfusions are the main treatment for patients with sickle cell disease. However, alloimmunization remains a major life-threatening complication for these patients, but the mechanism underlying pathogenesis of alloimmunization is not known. Given the chronic hemolytic state characteristic of sickle cell disease, resulting in release of free heme and activation of inflammatory cascades, we tested the hypothesis that anti-inflammatory response to heme is compromised in alloimmunized sickle patients, increasing their risk of alloimmunization. Heme-exposed monocyte-derived dendritic cells from both non-alloimmunized sickle patients and healthy donors inhibited priming of proinflammatory CD4+ type 1 T cells, and exhibited significantly reduced levels of the maturation marker CD83. In contrast, in alloimmunized patients, heme did not reverse priming of pro-inflammatory CD4+ cells by monocyte-derived dendritic cells or their maturation. Furthermore, heme dampened NF-kB activation in non-alloimmunized, but not in alloimmunized monocyte-derived dendritic cells. Heme-mediated CD83 inhibition depended on Toll-like receptor 4 but not heme oxygenase 1. These data suggest that extracellular heme limits CD83 expression on dendritic cells in non-alloimmunized sickle patients through a Toll-like receptor 4-mediated pathway, involving NF-kB, resulting in dampening of pro-inflammatory responses, but that in alloimmunized patients this pathway is defective. This opens up the possibility of developing new therapeutic strategies to prevent sickle cell alloimmunization.

AB - Transfusions are the main treatment for patients with sickle cell disease. However, alloimmunization remains a major life-threatening complication for these patients, but the mechanism underlying pathogenesis of alloimmunization is not known. Given the chronic hemolytic state characteristic of sickle cell disease, resulting in release of free heme and activation of inflammatory cascades, we tested the hypothesis that anti-inflammatory response to heme is compromised in alloimmunized sickle patients, increasing their risk of alloimmunization. Heme-exposed monocyte-derived dendritic cells from both non-alloimmunized sickle patients and healthy donors inhibited priming of proinflammatory CD4+ type 1 T cells, and exhibited significantly reduced levels of the maturation marker CD83. In contrast, in alloimmunized patients, heme did not reverse priming of pro-inflammatory CD4+ cells by monocyte-derived dendritic cells or their maturation. Furthermore, heme dampened NF-kB activation in non-alloimmunized, but not in alloimmunized monocyte-derived dendritic cells. Heme-mediated CD83 inhibition depended on Toll-like receptor 4 but not heme oxygenase 1. These data suggest that extracellular heme limits CD83 expression on dendritic cells in non-alloimmunized sickle patients through a Toll-like receptor 4-mediated pathway, involving NF-kB, resulting in dampening of pro-inflammatory responses, but that in alloimmunized patients this pathway is defective. This opens up the possibility of developing new therapeutic strategies to prevent sickle cell alloimmunization.

UR - http://www.scopus.com/inward/record.url?scp=84986216143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986216143&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.147181

DO - 10.3324/haematol.2016.147181

M3 - Article

C2 - 27229712

AN - SCOPUS:84986216143

VL - 101

SP - 1028

EP - 1038

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -